Enveric Biosciences, Inc.
ENVB evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ENVB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ENVB
Enveric Biosciences, Inc. is a neuro-pharmaceutical drug discovery and development platform company focused on psychedelic-inspired therapeutics, currently in early-stage development with no approved products and no revenue.
Key risk: No revenue, ongoing losses
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$6.1M
Cash Runway
—
Lead Asset
eb-003 (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for Enveric Biosciences, Inc..
Enveric Biosciences, Inc. is a neuro-pharmaceutical drug discovery and development platform company focused on psychedelic-inspired therapeutics, currently in early-stage development with no approved products and no revenue.
- Enveric is a neuro-pharmaceutical drug discovery and development platform company focused on psychedelic-inspired drug candidates [sec · filed 2026-02-10].
- The company has generated no reportable revenues since inception and expects to continue incurring losses for the foreseeable future [sec · filed 2026-02-10].
- As of 2026-06-30, Enveric reported net income of -$3.0M and shareholders' equity of $4.2M [sec].
- The company relies on external consultants, CROs, and CMOs to advance product development from early-stage work to clinical trial manufacturing and support [sec_mda · as of 2026-03-27].
- Enveric faces significant liquidity needs and has expressed substantial doubt about its ability to continue as a going concern [sec_mda · as of 2025-08-14].
What works
- Enveric utilizes a combination of internal and external efforts to advance product development, including an internal research team in Calgary, Alberta, Canada [sec_mda · as of 2026-03-27].
- The company is pursuing a novel therapeutic area (psychedelic-inspired drugs) that may address unmet medical needs [sec · filed 2026-02-10].
What to weigh
- Enveric has no approved products, no revenue, and expects losses to increase as development activities continue [sec · filed 2026-02-10].
- The company's product candidates are in early stages and may never receive regulatory approval or be successfully commercialized [sec · filed 2026-02-10].
- Enveric requires substantial additional funding to complete development and commercialization, and its ability to obtain such funding on commercially reasonable terms is uncertain [sec_mda · as of 2025-08-14].
- The company faces intense competition from companies with greater resources and experience [sec_mda · as of 2025-08-14].
From the filings
Quoted directly from source documents.
Enveric has no revenue and expects continued losses.
“We generated no reportable revenues since inception through September 30, 2025, we expect to continue to incur losses for the foreseeable future, and expect these losses to increase as we continue our product development activities.”
SEC filings · February 10, 2026
The company's product candidates are in early stages and may not reach development milestones.
“our dependence on the success of our prospective product candidates, which are in the early stages of development and may not reach a particular stage in development, receive regulatory approval, or be successfully commercialized;”
SEC MD&A · February 10, 2026
Enveric has significant liquidity needs and going concern risk.
“our significant and increasing liquidity needs and potential requirements for additional funding;”
SEC MD&A · August 14, 2025
The company relies on external partners for development.
“External efforts include work with consultants and increasingly substantial work at CROs and CMOs.”
SEC MD&A · March 27, 2026
Risks & what to watch (4)›
Key risks
- No revenue, ongoing losses — Enveric has no revenue and expects losses to increase as development continues [sec · filed 2026-02-10].
- Early-stage pipeline risk — Product candidates are in early development and may not reach clinical trials or receive approval [sec · filed 2026-02-10].
- Funding and going concern — The company needs substantial additional funding and has expressed going concern doubts [sec_mda · as of 2025-08-14].
- Regulatory and clinical delays — Delays in IND filings, clinical trials, or regulatory approvals could materially harm the business [sec · filed 2026-02-10].
What to watch
- Progress on IND filing and ability to initiate clinical trials for product candidates [sec_mda · as of 2026-08-14].
- Ability to secure additional financing to fund operations and development [sec · filed 2026-02-10].
- Any updates on preclinical or clinical data for psychedelic-inspired drug candidates [sec · filed 2026-02-10].
- Changes in regulatory landscape for psychedelic therapeutics [sec_mda · as of 2025-08-14].
Sources: SEC filings · SEC MD&A · Generated August 15, 2026 · How we verify sources →
Run Enveric Biosciences, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Enveric Biosciences, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.11 · 0% dilution
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
8
Total value held
$97K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 32,149 | $62K |
| advisorshares investments llc | 16,974 | $33K |
| jones financial companies lllp | 1,000 | $2K |
| blackrock, inc. | 51 | $99 |
| national bank of canada /fi/ | 1 | $2 |
| group one trading llc | 1 | $2 |
| danske bank a/s | 1 | $2 |
| wells fargo & company/mn | 1 | $2 |
Short Interest
as of May 21, 2026- % of float
- 45.7%
- Days to cover
- 0.1
- Shares short
- 886,509
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ENVB short interestGovernance
Frequently asked questions
What is the AI investment thesis for Enveric Biosciences, Inc.?
Enveric Biosciences, Inc. is a neuro-pharmaceutical drug discovery and development platform company focused on psychedelic-inspired therapeutics, currently in early-stage development with no approved products and no revenue.
What is Enveric Biosciences, Inc.'s lead drug candidate?
Enveric Biosciences, Inc.'s most advanced tracked candidate is eb-003 (Preclinical) for Mental health indication.
Who is the CEO of Enveric Biosciences, Inc.?
Dr. Joseph Edward Tucker Ph.D. is the chief executive officer of Enveric Biosciences, Inc. (ENVB).
Where is Enveric Biosciences, Inc. headquartered?
Enveric Biosciences, Inc. (ENVB) is headquartered in Cambridge, MA, United States.
What therapeutic areas does Enveric Biosciences, Inc. focus on?
Enveric Biosciences, Inc. develops therapies across Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.